Edition:
India

Nanobiotix Announces Phase I Study Results On NBTXR3


Thursday, 19 Sep 2019 

Sept 19 (Reuters) - NANOBIOTIX SA ::ANNOUNCED ON WEDNESDAY PHASE I STUDY RESULTS SHOW FIRST-IN-CLASS NBTXR3 COULD PRESENT AS A VALUABLE OPTION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA OR LIVER METASTASIS.NBTXR3 ACTIVATED BY STEREOTACTIC BODY RADIATION THERAPY (SBRT) WAS SAFE AND WELL-TOLERATED AT EACH OF THE FOUR (4) DOSE ESCALATION LEVELS.NBTXR3 REMAINED IN THE TUMOR FROM INJECTION THROUGH THE END OF RADIATION THERAPY WITHOUT LEAKAGE TO SURROUNDING HEALTHY TISSUE.STUDY SHOWED POSITIVE SIGNS OF EFFICACY FOR HEPATOCELLULAR CARCINOMA (HCC) PATIENTS, AS EVERY EVALUABLE PATIENT RESPONDED AND OVER HALF (62.5%) REACHED COMPLETE RESPONSE.GIVEN THAT THE SAFETY PROFILE WAS VERY GOOD, A 5TH DOSE ESCALATION LEVEL HAS BEEN ADDED TO THE TRIAL AND IS CURRENTLY RECRUITING.THESE RESULTS, HCC PARTICULARLY, ARE SIGNIFICANT AS THEY MAY WIDEN THE SCOPE OF INDICATIONS NBTXR3 CAN TREAT AND BOLSTER THE COMPANY’S GO-TO-MARKET STRATEGY.HAFNIUM OXIDE NANOPARTICLES ACTIVATED BY SBRT FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA AND LIVER METASTASIS: A PHASE I/II TRIAL. 

Company Quote

6.205
0.14 +2.31%
21 Oct 2019